Esjay Pharma Profile
Key Indicators
- Authorised Capital ₹ 80.00 Cr
as on 01-11-2024
- Paid Up Capital ₹ 73.07 Cr
as on 01-11-2024
- Company Age 2 Year, 3 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 20.00 Cr
as on 01-11-2024
About Esjay Pharma
The Corporate was formerly known as S3 Drugs Private Limited. The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 80.00 Cr and a paid-up capital of Rs 73.07 Cr.
The company currently has active open charges totaling ₹20.00 Cr.
The Key Managerial Personnel (KMP) at Esjay Pharma Private Limited India is Mariyam Shaffana as COMPANY SECRETARY. Shanmugam Muthusamy and Ayyavu Rajavel serve as directors at the Company.
- CIN/LLPIN
U24290TN2022PTC155725
- Company No.
155725
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
30 Sep 2022
- Date of AGM
29 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Chennai
Industry
Company Details
- Location
Kanchipuram, Tamil Nadu, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Esjay Pharma?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Mariyam Shaffana  | Company Secretary | 30-Jul-2024 | Current |
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Shanmugam Muthusamy  | Additional Director | 30-Jul-2024 | Current |
| Ayyavu Rajavel | Director | 30-Sep-2022 | Current |
Financial Performance of Esjay Pharma.
Esjay Pharma Private Limited, for the financial year ended 2023, experienced no change in revenue, with a 0% increase. The company also saw a no change in profitability, with a 0% increase in profit. The company's net worth witnessed no change by increase of 0%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets | |||||||
| Profit or Loss | |||||||
| Net Worth | |||||||
| EBITDA |
What is the Ownership and Shareholding Structure of Esjay Pharma?
In 2023, Esjay Pharma had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Saimirra Innopharm Private LimitedActive 24 years 9 monthsShanmugam Muthusamy and Ayyavu Rajavel are mutual person
Nuray Chemicals Private LimitedActive 12 years 6 monthsShanmugam Muthusamy and Ayyavu Rajavel are mutual person
Scitus Pharma Services Private LimitedActive 7 years 3 monthsShanmugam Muthusamy and Ayyavu Rajavel are mutual person
- Sthree Pharmaceuticals Private LimitedActive 9 years 4 months
Shanmugam Muthusamy and Ayyavu Rajavel are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Standard Chartered Bank Creation Date: 10 Apr 2024 | ₹20.00 Cr | Open |
How Many Employees Work at Esjay Pharma?
Unlock and access historical data on people associated with Esjay Pharma, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Esjay Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Esjay Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
